PRESENTATION

FY2025 — Results presentation

FY2025PDF · 62 pages4.2 MB
Audited
Results
and cash dividend declaration
for the year ended 30 June 2025

-- 1 of 62 --

2
Performance overview
Normalised
profit
+29%
to R15 210m
New
business1
-2%
to R26 486m
Headline
earnings
+30%
to R9 625m
Normalised
headline earnings
+30%
to R9 781m
1 Excluding discontinued products
Non-insurance
income
+12%
to R6 643m
excl. Sasolmed
+8%

-- 2 of 62 --

3
Key insights
Excellent start to the FY25-FY29 growth corridor
1
2
3
Robust FY25 operating performance across the Group
Clarity of strategy and growth through two business
composites
Acceleration of trends underpinning the relevance of the
Group’s Vitality Shared-value model and unique data
4

-- 3 of 62 --

4
FY25 performance

-- 4 of 62 --

5
Strong profit performance
Health 4 259 +7%
Life1 5 525 +14%
Invest 1 987 +29%
Insure 817 +229%
Bank -68 -85%
Other SA2 -515 +91%
SA 12 005 +22%
Vitality Health 1 188 +173%
Vitality Life 637 +70%
Vitality Network 554 +4%
Ping An Health Insurance 1 206 +7%
VHI - Other -291 -25%
Other Vitality -89 -54%
Vitality (UK and VG) 3 205 +70%
Normalised profit, ZARm
1 Includes Umbrella Funds
2 Vitality and Group initiatives and central costs
to R15 210m
+29%
Strong normalised profit growth
+22% +70%
FY25 profit growth:
FY25

-- 5 of 62 --

6
Supportive below-the-line performance
R million
Actual Actual
%	2025 2024
Normalised profit from operations 15 210 11 761 29%
Forex gains/(losses) -36 -87
1 DP finance lease impact -72 -105
Finance charges excl. 1DP finance lease -1 810 -1 750
Investment income and fair value gains on financial instruments 457 480
Other -254 -131
Profit before tax 13 495 10 168 33%
Taxation1 -3 937 -2 619
Profit after tax 9 558 7 549 27%
Profit not attributable to ordinary shareholders -231 -209
Loss on derecognition of intangible assets 112 35
Impairment- Held for sale 79 -
Impairment of intangible assets 55 6
Other headline earnings adjustments 52 3
Headline earnings 9 625 7 384 30%
Amortisation of intangibles from business combinations 104 90
Restructuring costs 61 37
Other normalised headline earnings adjustment -9 -
Normalised headline earnings 9 781 7 511 30%
1 The effective tax rate in the prior year was c.2% lower than the current rate as a result of a deferred tax asset raised on losses in the individual policyholder fund
Final dividend declared 201 cps
Full-year dividend 288 cps,
33% growth
5x dividend cover

-- 6 of 62 --

7
Robust cash generation lifts cash conversion ratio
Cash conversion ratio is calculated as Operating Cash Flow (R8 997m at 30 June 2025, from the ‘Additional Analyst Information’ document) over the IFRS normalised profit/(loss) from operations (R15 822m at 30 June 2025, from section A.1 Segment
Information of the ‘Audited Results’) net of IFRS income tax expense (R4 089m at 30 June 2025, from section A.1 Segment Information of the ‘Audited Results’)
Adjusted Net Cash Flow (Rbn)
Before ordinary dividends, capital
movements and one-offs
New
business
and tax
Operating
Cash Flow
R17.7bn
Cash
generated
from in-force
R9.0bn
Cash
generated
76.7%
cash
conversion
ratio
Cash uses
before capital
movements and
dividends
Net Cash Flow
excl. capital
movements
and dividends
Net Cash
Flow
Capital
movements
and dividends
R5.4bn
R1.6bn
-R1.7bn
Dividends
-R1.6bn
Debt capital
movements
Financing and
matching activities
R3.6bn
-R1.9bn
Investment in
growth
Discovery
Health
Discovery
Life
Discovery
Invest
Vitality
Health
Vitality
Life
Insure
-R6.8bn
New
business net
of external
funding
-R1.9bn
Tax
-R1.7bn
Finance
costs
-1.01
0.90
2.10
5.45
FY22 FY23 FY24 FY25
R3.8bn
-R0.5bn

-- 7 of 62 --

8
Robust growth in Group Embedded Value (EV)
15.7% Return on EV
▪ Non-economic experience
variances contributed positively to
the Group EV, offsetting a
strengthening to the basis
▪ Non-covered businesses: Positive
contributions from PAHI and Insure,
in line with profit, and the break-even
of the Bank, further supported
growth
▪ Additional uplift from economic
impacts, including forex movements
Opening EV
Value of new business
Unwind of risk discount rate	
Non-economic experience
variances and methodology &
assumption changes
Operational EV
Economic experience variances	
and methodology & assumption
changes
Non-covered businesses
Forex
Finance costs, investment
income & other
Change in captial & dividends
Closing EV
R124 994m
R110 354m
R126 554m

-- 8 of 62 --

9
Focus on quality new business
Health1 9 573 +12% 1 343 +7%
Life 3 203 -10%
Individual Life 2 733 -2%
Group Life and UF 470 -41%
Invest 3 430 +4%
Insure 1 361 -2%
Bank 2 338 +29%
Vitality 546 +33%
SA1 18 113 +5% 3 681 +20%
Vitality Health 2 851 +3%
Vitality Life 2 499 +28%
Vitality Network 1 977 +4%
Ping An Health Insurance 3 023 +22%
VHI - Other 985 +5%
Other Vitality
Vitality (UK and VG) 8 373 +16% 2 962 +5%
Total excl. Sasolmed 26bn +8% 7bn +12%
Total 26bn -2% 7bn +12%
New
business
Non-insurance
income	ZARm
1 Excl. Sasolmed
+8%
New business
Excl. Sasolmed in prior period
0
5 000
10 000
15 000
20 000
25 000
30 000
FY01	
FY02	
FY03	
FY04	
FY05	
FY06	
FY07	
FY08	
FY09	
FY10	
FY11
FY12	
FY13	
FY14	
FY15	
FY16	
FY17	
FY18	
FY19	
FY20	
FY21	
FY22	
FY23	
FY24	
FY25
Sasolmed
FY25
to R26 486m

-- 9 of 62 --

10
Strong client growth
Vitality lives includes customers in the UK, and lives covered globally including free AIA members and corporates
SA Vitality excl. PAHI PAHI
0
5
10
15
20
25
30
35
2021 2022 2023 2024 2025
Millions
to 6.4m
+6% to 10.4m
+25% to 32.1m
+17%
0
1
2
3
4
5
6
7
2021 2022 2023 2024 2025
Millions
0
2
4
6
8
10
12
2021 2022 2023 2024 2025
Millions

-- 10 of 62 --

11
FY25-FY29 growth corridor

-- 11 of 62 --

12
Discovery businesses have been built organically
Group operating profit
CPI + 10%
Previous Organic Growth Model
ESTABLISHED
EMERGING
NEW
~3
years
~5
years
Profit growth of
CPI + 5%
Profit growth of
CPI + 30%
Growth in
investment of
CPI + 10%
90%
20%
-10%
of profit
of profit
of profit

-- 12 of 62 --

13
0%
10%
20%
30%
0
2
4
6
0%
20%
40%
60%
80%
0%
5%
10%
15%
20%
25%
0%
10%
20%
30%
-20%
-10%
0%
10%
20%
30%
40%
The result is different phases of growth
% spend
on new
Dividend
cover
Cash
conversion
ratio
(normalised history)
Normalised
profit
growth
FLR
Normalised
RoE
Scaled organic growth
15-20%
RoE
15-20%
CAGR
c5%
Spend on
new
10-20%
FLR
≤5x
Dividend
cover
60-70%
Cash
conversion ratio
Forward looking information on this slide is for illustration and has not been reviewed or reported on by the auditors and reflects the average expected over the time frame
Illustrative ranges
Big investments in New	Unfettered organic growth
Average 13%	Average 20%
Average 22%
Average
3%
4.6x 5.7x
CAGR
IFRS 4
9%	CAGR 22%
8% 15%
56%	60%
Average
Average
Average
Average
Average
Average
FY
2006
FY
2007
FY
2008
FY
2009
FY
2010
FY
2011
FY
2012
FY
2013
FY
2014
FY
2015
FY
2016
FY
2017
FY
2018
FY
2019
FY
2020
FY
2021
FY
2022
FY
2023
FY
2024
FY
2026
FY
2027
FY
2028
FY
2029
FY
2025

-- 13 of 62 --

14
Strong delivery in the first year of the five-year growth
corridor
Strong normalised profit growth
IFRS 17
0
2 000
4 000
6 000
8 000
10 000
12 000
14 000
16 000
FY01	
FY02	
FY03	
FY04	
FY05	
FY06	
FY07	
FY08	
FY09	
FY10	
FY11
FY12	
FY13	
FY14	
FY15	
FY16	
FY17	
FY18	
FY19	
FY20	
FY21	
FY22	
FY23	
FY24	
FY25
14%
15-yr CAGR
0%
5%
10%
15%
20%
25%
30%
SA excl
bank
Bank Vitality Total
FY25 cumulative profit growth contribution
29%
17%
+ 5%
+ 8%
Target
corridor of
growth
Outperformance in FY25

-- 14 of 62 --

15
On track to achieve five-year CAGR ambition
Forward looking information on this slide is for illustration and has not been reviewed or reported on by the auditors and reflects the average expected over the time frame
Strong performance in the first year of delivery has increased
confidence in achieving this ambition over the period
% spend on
new
Dividend cover
Cash
conversion ratio
Normalised
profit growth
FLR
Normalised
RoE
Guidance
15-20%
RoE
15-20%
CAGR
c5%
Spend on new
10-20%
FLR
≤5x
Dividend cover
60-70%
Cash conversion ratio
15.4%
FY25
16.8%
FY25
29%
FY25
3%
FY25
76.7%
FY25
FY25
5x
FY25
Operating profit
corridor
(Applying CAGR target
to FY24 profit)	15%
20%
-
5 000
10 000
15 000
20 000
25 000
30 000
35 000
FY20 FY21 FY22 FY23 FY24 FY25 FY29

-- 15 of 62 --

16
Group is financially strong
1 Normalised for COVID-19 reserve impact, refer to Annexure A; 2 Capital Adequacy Ratio; 3 Comprehensive Solvency Ratio, definition set by China Banking and Insurance Regulatory Commission
Improving cash conversion Strongly capitalised FLR decreasing
Group cash conversion ratio1 Financial leverage ratio	Solvency cover
DHMS solvency
(unaudited)
Jun 24 Cover Jun 25 Cover
Life 1.8x 1.9x
Insure 1.6x 2.1x
VH 1.6x 1.8x
VL 2.0x 2.0x
Bank2 1.3x 1.2x
PAHI3 3.2x 3.3x
76.7%
30%
40%
50%
60%
70%
80%
FY21 FY22 FY23 FY24 FY25
10%
15%
20%
25%
FY22 FY23 FY24 FY25
16.8%
31.7%

-- 16 of 62 --

17
Capital allocation framework
Strategic choices
Normalised profit
growth
Cash conversion
ratio
Normalised
RoE
Leverage
% spend on new
Dividend cover
15-20%
CAGR
FY25-FY29 60-70%FY25-FY29 15-20%
FY25-FY29 ≤5x
FY25-FY29
c5%FY25-FY29
10-20% FY25-FY29
Forward looking information on this slide is for illustration and has not been reviewed or reported on by the auditors and reflects the average expected over the time frame

-- 17 of 62 --

18
Strong growth platforms

-- 18 of 62 --

19
Acceleration of disruptive environmental trends
Nature of
risk
Technology
Social
responsibility
Demographic
• Risk due to modifiable behaviours: 37% of
healthcare expenses are due to modifiable
behaviours
• Causality of behaviour change: mortality,
sickness and healthcare costs are significantly
impacted by behaviour change. This impact is
universal; it holds across age, gender, and
health status; and is elastic - so even more
significant for people who are older and sicker
Nature of risk
Demographic
Technology
Social responsibility
• Ageing populations impact on healthcare:
there is a corresponding rise in the incidence
of chronic diseases as populations age,
leading to a surge in healthcare expenses.
Ageing demographics also contribute to a
growing demand for long-term care services,
further straining financial resources
• Heightened obesity levels: obesity rates are
increasing and the impact on healthcare
costs is substantial
• AI and machine learning advances:
Agentic AI is emerging as a transformative
force, with autonomous systems reshaping
industries, workforces, and competitive
dynamic
• Benefits and costs of drug innovations:
The rise of GLP-1 treatments is altering
consumer behaviour, and softening
demand in the food and beverage sector
• Stakeholder needs are more widely
defined: businesses face pressure to
create value for all stakeholders through
their products, services and client
journeys
• Evolution of value-based care:
accelerated pressure on stakeholders to
improve quality of care and decrease
costs, through a patient-centric approach
of global
deaths due
to NCDs
~75%
Mortality risk
from no to
high exercise
(45-65 yrs)
-58%
Requires a deep understanding of risk and how to
manage it
Requires preventative interventions and disease
management programmes to improve population health
Requires sophisticated analytics to deliver hyper-
personalised solutions
Requires a shared-value business model
of the
population will
be 60+ by 2030
25-35%
Per person
retirement gap
in the US (2023)
$60k
Potential
medical cost
savings by year
10 due to GLP-1s
~$18bn
AI infrastructure
planned spend by
US tech firms in
2025
~$400bn
of traditional
Medicare patients
in an accountable
care relationship
with a provider
53.4%
global
sustainable
AUM
$3.5tr

-- 19 of 62 --

20
Rich multi-market dataset that integrates behavioural and
operational data
Claims
Screenings	
Device
Demographics
Incentive partner	
preferences
Telematics	
Lifestyle	
(sleep +	
nutrition)
Underwrriting	
Pathology &	
radiology	
Vitality	
Money
Workflow
processing
App &
Web logs
Virtual agent &
live chat
Sales agent
data
Transactions/
payments
Marketing
comms
System logs
Transaction	
data
>100 AI models and
initiatives developed,
leveraging advanced AI
techniques and tools
>150 internal data
pipelines integrating data into
big data environments, with
built-in privacy protections
>72 individual databases
housing structured data
across the business
>1.4 petabytes
Structured data (health,
wellness, and mortality) &
unstructured data (images,
emails, and voice recordings
>25 years of historical
structured & unstructured
data captured and retained
OPERATIONAL DATA
BEHAVIOURAL DATA
Pricing & benefit
optimisation
Behaviour
assessment &
risk prediction
Behavioural
coaching
Operational
efficiency

-- 20 of 62 --

21
Data is structured in a way that enables cross-domain
insights linking behaviour and risk
Absolute impact of REM sleep on insure AvE of damage
frequency
REM sleep has a significant impact on driving risk across all statuses
Relative impact of REM sleep on insure AvE of damage
frequency
Example: Understanding the link between REM sleep and risk of car accidents
140%
120%
100%
80%
60%
0%
40%
20%
Blue Bronze Silver Gold Diamond
Vitality drive status
AvE Accident damage frequency
±15% absolute
impact across all
statuses from lower
REM sleep
>1-hour avg REM
<1-hour avg REM
1.3x
1.25x
1.2x
1.15x
1.10x
1.05x
Blue Bronze Silver Gold Diamond
Vitality drive status
AvE Accident damage frequency
120% -> 105%
= 1.14 130% -> 115%
= 1.12
110% ->95%
= 1.15
90% -> 75%
= 1.20
75% -> 60%
= 1.25

-- 21 of 62 --

22
This has enabled the evolution of the Vitality Shared-value
Insurance model driven by hyper-personalisation
Proprietary
data
Dynamic
risk
assessment
Vitality.AI
recommender
Incentivised
engagement
Insurance
integration

-- 22 of 62 --

23
+22% +70%
FY25 profit growth:

-- 23 of 62 --

24
Discovery SA
Discovery Bank	
Discovery Insure	
Discovery Invest	
Discovery Life	
Discovery Health
Discovery Corporate Employee Benefits reported as a division of Discovery Life

-- 24 of 62 --

25
Strong focus and ambition for Discovery South Africa
1 Retail affluent market share
2 Excluding white labelled funds
1 2 3
Ensuring each business is a market
leader in terms of market share, margin,
product innovation and enhanced
customer value
Scale Discovery Bank with an
ambition to achieve 2m clients and
R3bn in profits in FY29
# 1
fastest growing
short-term insurer
by GWP
3rd
largest in net flows2
# 1
market share
# 1
market share1
Each product sits on the Bank, with a
consistent architecture, and the Bank
Operating System as the single
interface for the Discovery SA Composite

-- 25 of 62 --

26
Discovery Bank
Deposits Normalised profit	Revenue (NII+NIR)
+30% +26% -85%	+31%
to 1.2m to R23.3bn to (R68m)	to R2.4bn
Advances
+39%
to R9.2bn
Total
accounts
Total
clients
+32%
to 3.0m
NII includes the allocation of interest earned on the bond trading portfolio (recognised at fair value gains in the income statement)
2021 2022 2023 2024 2025 2021 2022 2023 2024 2025 2021 2022 2023 2024 2025
NII NIR
2021 2022 2023 2024 2025
Profitable
in H2
H1 2020	
H2 2020	
H1 2021	
H2 2021	
H1 2022	
H2 2022	
H1 2023	
H2 2023	
H1 2024	
H2 2024	
H1 2025	
H2 2025
Accounts Clients
H1

-- 26 of 62 --

27
0%
1%
2%
3%
4%
5%
6%
Credit card Homeloans
Dec-24 Jun-25
Quality lending with engaged clients
Monthly advances by product (Rm)
1 Market average source: Annual Financial statements of the top 5 SA banks per product category, 2 % top of wallet refers to the proportion of clients that are estimated use Discovery Bank as their primary bank account for spending, based on breadth
of spend, value of spend relative to income, and type of spend. Rebased to SCF or transaction only
Advances CLR Engagement
Homeloans >R2bn balance
as at 8 Sep-25
Credit loss ratio by product*
Jul-21	
Oct-21	
Jan-22	
Apr-22	
Jul-22	
Oct-22	
Jan-23	
Apr-23	
Jul-23	
Oct-23	
Jan-24	
Apr-24	
Jul-24	
Oct-24	
Jan-25	
Apr-25
Credit Card Advances DTA Overdrafts
Access Facility Lending Home loans
Personal Loans
Revolving Credit
Facility launched
Homeloans
launched
Personal loans
launched
Relative % top of wallet by product suite
Market average (Dec-24)
0%
100%
200%
300%
400%
500%
600%
700%
800%
900%
SCF or
Transaction
only
SCF /
Transaction +
RCF
SCF/
Transaction +
HL/PL
SCF/Transaction
+ RCF + HL/PL
Transaction
Single Credit Facility
Overdrafts
Revolving credit facility

-- 27 of 62 --

28
NII and NIR cohort analysis
NII PCPM by months on book NIR PCPM by months on book Profit PCPM by months on book
Based on internal analysis and excludes Not Good Standing; Indexed to month 0 of 2023-01 cohort
2023-01 cohort 2025-06 cohort
0
5
10
15
20
25
30
0 2 4 6 8 10 12 14 16 18 20 22 24 26 28
0
5
10
15
20
25
30
0 2 4 6 8 10 12 14 16 18 20 22 24 26 28
0
5
10
15
20
25
30
0 2 4 6 8 10 12 14 16 18 20 22 24 26 28

-- 28 of 62 --

29
A full-service, digital shared value retail Bank
Fastest growing1
retail Bank in
South Africa with
market-leading
digital capabilities
Four key hypotheses
Full retail banking product
suite1 |
Shared-value banking
model2 |
Digital-first with
advanced AI capabilities3 |
Operating system of the
composite4 |
1 Using organic balance sheet growth; The analysis considers year-on-year growth, retail deposits: adjusting for the impact of any mergers or acquisitions, retail advances: credit cards (excl. overdrafts) and home loans. It does not consider other
factors such as profitability, customer experience and operational scale. Based on June 2025 BA900s

-- 29 of 62 --

30
1993	
1995	
1997	
1999	
2001	
2003	
2005	
2007	
2009
2011
2013	
2015	
2017	
2019	
2021	
2023	
2025
Non-scheme products
Restricted schemes
DHMS
2021 2022 2023 2024 2025	2021 2022 2023 2024 2025
Discovery Health
1 Sasolmed contributed R2 510m to new business for FY2024
2 Reported number of lives under administration is not a unique count
Normalised profit New business Non-scheme growth	Membership
+7% -14% 3.98m
to R4 259m to R9 573m Lives under
administration2
>448k lives
+18%
Sasolmed1 closed scheme
Jan-18	
Aug-18	
Mar-19	
Oct-19
May-20	
Dec-20
Jul-21
Feb-22	
Sep-22	
Apr-23	
Nov-23	
Jun-24	
Jan-25
Flexicare
Gap cover
Healthy Company
AHI
Jun
-25
(Excl. Sasolmed)
+12%
VHIA

-- 30 of 62 --

31
0%
1%
2%
3%
2021 2022 2023 2024 2025
Upgrades Downgrades
0%
5%
10%
15%
20%
25%
30%
35%
40%
0
5
10
15
20
25
30
35
2021 2022 2023 2024 2025
Reserve Actual solvency Required solvency
Discovery Health Medical Scheme (DHMS): continued excellent
performance in a complex environment
Membership and open market share as at June 2024 Plan changes exclude impact of plan closures
Membership Customer satisfaction Solvency
58.0% market share Low proportions of members change plans, with
more members upgrading than downgrading:
Lapses continue to remain stable
R32.2bn
31.7%
AAA
projected unaudited reserves
projected unaudited solvency
credit rating
R billion
95% no plan changes
DHMS Rest of the industry
Others 0%
2%
4%
6%
8%
10%
2021 2022 2023 2024 2025

-- 31 of 62 --

32
Personal Health Pathways (PHPs) drives positive behavioural
change while delivering positive impact for DHMS
PHP activation and engagement statistics as at 4 September 2025
Personal Health Fund (PHF); Next Best Action (NBA)
361k
activated lives
Member activation and engagement Driving behaviour change through incentivisation
3%
11%
3% 3%
16%
56%
52%
25%
17%
9%
19%
52%
2024 2025
Online NBAs
Visit your
practitioner
Cancer & other
screenings*
Vaccines
Diagnostic
tests
Collect your
medicine
27 NBAs in 6 categories
383%
increase in the completion rate
from 2024 to 2025
5.2x
increase in total number of
completed actions
357k
Health actions
completed
1.95m
Exercise actions
completed
R27.2m
rewards earned
R197m
PHF funds earned
69%
of all health and exercise actions
completed are from chronic members
Chronic
*Include screenings for: Colon cancer, Mammogram, Pap/HPV, Foot (podiatrist), DR, Prostate cancer

-- 32 of 62 --

33
2021 2022 2023 2024 2025	2021 2022 2023 2024 2025 2025	2025 2021 2022 2023 2024 2025
Discovery Life
Normalised profit Cash generation Capital and liquidity
+14%
to R5 525m (Individual Life)
SCR
coverage
Total
liquidity
192%
2 675m
1X
ILT
125%
SCR
Target
-10%
to R3 203m
Market share source: NMG market report Q2 2025
Discovery Life Ltd
New business
Maintained 27% market share of
the underwritten retail risk business
3,3
Covid
impact
-0,7
1,5
2,2
-0,2
+52%
Discovery Life Ltd
Cash flow before financing initiatives
and dividends to Group (Rbn)	+11% (Individual Life)
-2%
Discovery Life includes Individual Life and Corporate & Employee Benefits
IFRS 17

-- 33 of 62 --

34
Premium, fees &
investment
income
Cashflow before
financing/
funding to
Group
Robust claims performance driving strong cash generation
Excellent claims experience validating the
shared value model
Strong cash generation in Life and Invest driven
by favourable claims and market growth
Mortality experience by Vitality status relative to expected
(AvE)
None Blue Bronze Silver Gold Diamond Financing
repayment
Dividend to
Group
Cash outflows
R3.3bn
R23.4bn
-R12.1bn
Claims
-R4.4bn
Operational
costs
-R3.6bn
New
business
cash
conversion
ratio
~60%
(Rbn)
R1.6bn R1bn
Jul 2020 – Jun 2025
Long-term expected
FY25
-78%
100%

-- 34 of 62 --

35
June 2024
New Business
Expected Unwind excl.
new business
Experience Variances
Basis changes
Dividends
Other
June 2025
45 948 461
4 663
1 129
737
- 988
214 52 164
June 2024
Assumption
changes
Indiv Life	
volumes
Group Life	
volumes
Other
June 2025
Positive operating variances and robust EV growth with VNB
margin impacted by lower volumes
Growth in Embedded Value	VNB margin impacted by lower NB
volumes
3.8%
Individual Life:
5.0%
(20.0% IRR)
2.1%
Life (excl. Invest) VNB margin (%)
Individual Life:
3.8%
(18.5% IRR)
15.7% Annualised RoEV*
*Before dividend payments.
13.2% excl. economic updates
Mortality and morbidity
Persistency
Premium and fee income
Policy alterations
Other
Total non-economic
Economic
Total
Discovery Life Ltd EV variances (Rm)
R841m
R1 129m
Positive operating variances
Discovery Life Ltd EV growth (Rm)
Persistency
Premium & fee income
Other
Total non
-economic	
Economic
Total
Policy
alterations*
Mortality & morbidity
*Defined action plan being phased in to address policy alterations
June 2024	
June 2025	
June 2025	
June 2024

-- 35 of 62 --

36
Discovery Invest
Source: Ninety One; Net flows excluding reinvestments, Money Market and FOF. Including both retail and institutional flows
Normalised profit
Assets under
administration Net flows	New business
+29% +15% 14%	+4%
to R1 987m to R179bn Since 2015	to R3 430m
2021 2022 2023 2024 2025
API from guaranteed
Discovery
Invest
Other asset managers
+9%
Excl.
guaranteed
2021 2022 2023 2024 2025
Once-off items
+15%
Excl.
one-offs
Jan-18	
Sep-18	
May-19	
Jan-20	
Sep-20	
May-21	
Jan-22	
Sep-22	
May-23	
Jan-24	
Sep-24	
May-25
One off items
IFRS 17

-- 36 of 62 --

37
Well positioned to grow in the current context
Introducing private market
investments to Discovery clients
Risk
Return
 Efficient frontier
including public
and private
markets
Efficient frontier
including public
markets
Cogence Diversified
Markets Portfolio
Cogence Global
Diversified Markets
Portfolio
15%
private market
exposure
15%
private market
exposure
Cogence in partnership
with BlackRock
>R28bn assets under management
65 68 71 74 77 80 83 86 89 92 95
Leveraging actuarial dynamics to
combine shared value with
longevity protection
Guaranteed income
from age 80
Income boosts of
up to 50%
>90% more cost effective than a
traditional fixed annuity

-- 37 of 62 --

38
Discovery Insure
Solvency	Normalised profit Insurance revenue
+229% +8%
to R817m to R6 217m
212%	-2%
to R1 361m
Gross new business
2021 2022 2023 2024 2025 2021 2022 2023 2024 2025	2021 2022 2023 2024 2025	2021 2022 2023 2024 2025
IFRS 17

-- 38 of 62 --

39
Recovery driven by deliberate structural improvements
Improved loss ratio from management actions across the value chain
Upfront
selection Persistency Claims Profitability
New business book based on insurance risk
exposure
Quality of the new business book
has strengthened
75%
80%
85%
90%
95%
100%
2019 2020 2021 2022 2023 2024 2025
Superior risk profile Average risk profile
-0.4%
-1.2% -0.4% -0.5%
-1.3%
-1.4%
-2.0%
-0.9%
-2.5%
Claims
initiatives
Other
external
factors
FY24
loss
ratio
FY25
loss
ratio
Expected
weather
improve-
ment
Upfront
selection
Under-
writing
actions
Pricing
actions
Selective
lapsation
uplift
Unexpected
weather
improve-
ment
Duration
uplift
FY25 loss
ratio before
non-
recurring
factors

-- 39 of 62 --

40
Discovery SA
Proprietary
data
Dynamic
risk
assessment
Vitality.AI
recommender
Incentivised
engagement
Insurance
integration
Discovery Bank	
Discovery Insure	
Discovery Invest	
Discovery Life	
Discovery Health

-- 40 of 62 --

41
Vitality
Vitality Health	
International	
Vitality Network	
Vitality UK

-- 41 of 62 --

42
Considerable work done to restructure the business to unlock
efficiencies, globalise capabilities and deliver growth
Announcement of a
single global business, Vitality
Phase 1:
Exploration
Aug – Oct 2024
Phase 2:
High-level operating model
Nov 2024 – Feb 2025
Phase 3:
Growth strategies
and efficiencies
Mar – Jun 2025
Phase 4a:
Regionalisation
Phase 4b:
Vitality AI
Jul 2025 onwards
Efficiencies through rolling off contractors
and removing duplicate roles
Clearly identified growth opportunities
Created the Vitality
Distribution
Academy to
support sales
Established Global
IP hubs to harness
best practice
Unified our approach to
development, design and
delivery of technology
assets underpinned
by Vitality AI
Regionalisation
Deliver
Vitality AI

-- 42 of 62 --

43
USA
NETWORK	UK

-- 43 of 62 --

44
Vitality UK
Operating profit Premium income Lives covered	New business
+126% +15% +7%	+14%
to £77.7m to £1.3bn to 2.0m	to £228m
2021 2022 2023 2024 2025 2021 2022 2023 2024 2025 2021 2022 2023 2024 2025	2021 2022 2023 2024 2025
2m
lives
IFRS 17

-- 44 of 62 --

45
Vitality UK’s differentiated brand is a powerful asset
Brand awareness at all-time
high, surpassing competitors
UK at the centre of building a
global brand
H2 2014	
H1 2015	
H2 2015	
H2 2015	
H1 2016	
H1 2017
No…
H1 2019	
H2 2019	
H1 2020	
H2 2020
Early H2 2021
H2 2021	
H1 2022
No…
H1 2023	
H2 2023	
H1 2024	
H1 2025
Competitor Average Vitality
+357%
Growth since 20141
1 H1 2025 Vitality Brand Survey, Immerse UK
64
63
Reviewed and
verified to meet the
requirements of
the UK Code of
Broadcast
Advertising
Peer reviewed by LSE
by engaging with the
Vitality Programme
Up to
5 years longer
Elevated brand messaging that
highlights shared value
Iconic core brand assets
New global tagline
Unique brand campaigns
Stanley
No
measure
No measure
Vitality Pink
Roundel

-- 45 of 62 --

46
VitalityHealth
Normalised profit Premium income1 New business Lives covered
+174% +16% +3% +3%
to £50.6m to £814.5m to £121.4m to 1.1m
IFRS 17
1 Insurance revenue
2021 2022 2023 2024 2025 2021 2022 2023 2024 2025 2021 2022 2023 2024 2025 2021 2022 2023 2024 2025

-- 46 of 62 --

47
Pricing actions and stabilising claims experience have
restored margins
1. Premiums rebased successfully
to claims experience
2. Robust and selective retention
Premiums vs claims PLPM
(3-month average, rebased to Jul-23)
Operating margin vs earned
premiums
0%
2%
4%
6%
8%
10%
12%
14%
2018 2019 2020 2021 2022 2023 2024 2025 2026
(plan)
Margin (actual) Margin (plan)
7.5% margin
COVID-19 impact
3. Margin recovery combined with
revenue growth
c.15% Renewal lapse rate
lower than plan (FY 2025)
Expected margin
(FY 2026)	7.5%
Lapse rates and claims relativity by
Vitality status
Bronze Silver Gold Platinum
Individual SME Claims relativity
Overall
lapse rate
Bronze Silver Gold Platinum
SME	Individual Claims relativity
90%
95%
100%
105%
110%
115%
120%
125%
130%
Jun-23 Dec-23 Jun-24 Dec-24 Jun-25
Premium PLPMs Claims PLPMs (rolling 3m)
Claims and premium
PLPMS back in line

-- 47 of 62 --

48
VitalityLife
Normalised profit Premium income Lives covered	New business
IFRS 17
2021 2022 2023 2024 2025 2021 2022 2023 2024 2025 2021 2022 2023 2024 2025 2021 2022 2023 2024 2025
+70% +11% +28% +12%
to £27.1m to £447.8m to £106.4m to 904k lives

-- 48 of 62 --

49
New business API (£’m)
Momentum in new business performance has continued,
driven by Vitality Shared-value Insurance
Step change in new business
Increased footprint to unlock
future growth Establishing solid market share
1.GenRe Protection Pulse
2.Swiss Re Term & Health Watch 2025 Report. 3rd in ‘New Term APE (with and without CI)’, ‘New IP policies’, ‘New CI APE’ in 2024 calendar year.
83.1
106.4
FY24 FY25
+28%
Advisers writing
(rolling 3 months)
VitalityLife market share1
Jun 24	
Jul 24
Aug 24	
Sep 24	
Oct 24	
Nov 24	
Dec 24	
Jan 25	
Feb 25	
Mar 25	
Apr 25	
May 25	
Jun 25
+30%
7.4%
8.4%
10.4% 10.9%
13.5%
FY21 FY22 FY23 FY24 FY25
3rd largest
market share2
3 425
2 703

-- 49 of 62 --

50
Growth is focused on writing quality new business with no
compromise to new business profitability
VL quote competitiveness on
portals
Competing selectively –
priced at a premium and
not buying share
Benefiting from scale and
expense efficiencies
Net change in margins (CSM
and RA)
Drivers of new business value
(rebased to FY24 H1)
New business net value (£m)
(CSM and RA, less onerous new
business)
.
Resulting in significant
change in new business
value generated
FY24 H1 FY24 H2 FY25 H1 FY25 H2
Sales
Underlying profitability
Per policy initial expenses1
1. VL's premium relative to average of cheapest 5 providers on a quote (an indicator of premium competitiveness)
2. Underlying profitability defined as the % of PV of premiums available to cover initial expenses and profit. FY25 shown before basis changes for consistency with the previous periods
Optimiser premium lowest for
54% of quotes
16.1
46.9
7.1
53.9
FY24 FY25
Reported net value Basis Change
52.1
8.9
9.1 13.3
39.0
New Business
Interest Accretion
VIF Monetisation
Release to Earnings
Basis change
109%
95%
6%
54%
Standard Optimiser
Compete ratio1 Lowest premium
+73%
-28%
100%
Compete ratio1
Underlying profitability2
Per policy initial expenses
Change in margin (£m)
(CSM and RA)
.

-- 50 of 62 --

51
NETWORK

-- 51 of 62 --

52
Vitality Network
Integrated API by
insurance partners
+24%
to $1 951m
Normalised profit
+7%
to $30.5m
2021 2022 2023 2024 2025	2021 2022 2023 2024 2025
Revenue
+8%
to $109m
2021 2022 2023 2024 2025
Insurance partners
membership
+27%
to 6.7m
2021 2022 2023 2024 2025

-- 52 of 62 --

53
Positive impact of shared value observed across markets
Blue Bronze Silver Gold Diamond
Relative claims rates
57%
lower
Relative lapse rates
53%
lower
Blue Bronze Silver Gold Diamond
The Shared-value model is creating
value for both John Hancock Vitality
customers and John Hancock
of Vitality members
with high blood
pressure or high
cholesterol readings
are now in-range
50% 45%
of Vitality members
reported a
reduction in BMI
of Vitality members
reported similar or
better health YoY
80%
of John Hancock
customers use
Vitality
66%
Reduction in lapse rates for
Vitality Plus members on
higher status levels relative to
Non-Vitality Plus members
60%
2019 2024
6%
increase in
proportion of
off-Blue
members
Member engagement
Relative claims rates
39%
lower
Relative lapse rates
48%
lower
Consistent
member
engagement
Member engagement
Relative claims rates
70%
lower
Relative lapse rates
63%
lower
2019 2025
61%
Member
engagement
% of members
earned a point
Member engagement
Bronze Silver Gold Platinum
Bronze Silver Gold Platinum
2019 2024
Blue Bronze Silver Gold
Blue Bronze Silver Gold
4th largest life insurance market 3rd largest life insurance market 1st largest life insurance market

-- 53 of 62 --

54
Positioning the business for future scale and growth
1 Restructuring of existing
partnerships
Launching the next evolution of
Vitality products through Vitality AI
Rapid pursuit of new opportunities
across Europe and North America
2
3 Opportunity to establish optimal, long-
term partnerships in Europe, following
the Generali partnership termination
Vitality AI launch in November 2025 Leveraging Vitality AI
to drive engagement
Enhancing Shared-value
outcomes by investing back
into the AIA Vitality
partnership, alongside AIA
Collectively committed to 5m
lives by 2030, with restructured
economics to simplify and
capture the emergence of value
Termination of the
partnership due to
strategic misalignments
Leveraging the launch of Vitality AI
to drive growth in North America

-- 54 of 62 --

55
Vitality AI is the future of behavioural
insurance in a hyper-personalised world
*Underwritten by the global reinsurance market – with a panel of the big six reinsurers participating
Proprietary
Data
Dynamic Risk
Assessment
Vitality.AI
Recommender
Incentivised
Engagement
Insurance
Integration Wedge
funding
Dynamic
pricing Vitality
Product
Reinsurer
panel*
World-class
technology
platform
Vitality
engagement
toolkit
Vitality Global
Partner and
Rewards Network
Personalised
communication
Habit
laddering &
gamification
>60m
Life years of
behavioural linked
insurance data
Global data
engineering
Habit
index
Propensity
model
Reward elasticity
model
Next best
action model
Device-
led
Causal
inference
model
Value
model
HealthyFutures
algorithm

-- 55 of 62 --

56
Case study of the value to a life insurer and life insurance
member driven by the shared-value model
Initial internal modelling based on a European insurer
Value to the insurer Value to the member
Case study based on initial internal modelling of a Term Life portfolio with European market
dynamics. Range provides an indication of value based on underlying market dynamics and
engagement with Vitaliy, with engagement ranging between 20 – 40%
Member value derived from their Vitality term life policy over the lifetime of the policy. Case
study based on a 40-year-old male who purchases an indexed term life policy with a 20-year
term and £500k sum assured
Relative VNB margin uplift Case study: lifetime member uplift
Bronze Silver Gold Platinum
-1.3 to 11.5 times year 1 premium
Non-optimised
Term Life
Shared-value
actuarial
benefits:
Improved lapses,
claims and
reinsurance
premiums
Value shared
with member:
Through
insurance
integration
structure
Shared-value
commercial
benefits:
Additional
growth and
better business
mix
Total value
48 – 79% increase in value

-- 56 of 62 --

57
2021 2022 2023 2024 2025
Investment income and gains
Profit before investment
income and gains
Ping An Health Insurance
PAHI’s operating
results pre-tax
Discovery’s operating
result after tax
PAHI licence
new business1
PAHI licence
earned premium1
+22% +10% +25%	+21%
to RMB2.5bn
(RMB636m DSY’s share)
to RMB479m to RMB4.8bn	to RMB17.8bn
Lives
+17%
to 32.1m PAHI licence lives
1 100% of PAHI
2021 2022 2023 2024 2025	2021 2022 2023 2024 2025 2021 2022 2023 2024 2025	2021 2022 2023 2024 2025
Tax benefit
DSY Profit After Costs
+8%
before investment
income and 2024
COVID release

-- 57 of 62 --

58
0
2
4
6
8
10
12
14
2021 2022 2023 2024 2025
Strong market fundamentals continue to support high quality,
sustainable earnings
Continued growth in
market share
PAHI market share (%) 2
6.3%
7.0%
7.7% 8.1%
9.6%
2021 2022 2023 2024 2025
Superior operational
margin
Net profit margin 3
-4%
-2%
0%
2%
4%
6%
8%
10%
12%
2019 2020 2021 2022 2023 2024
Balance sheet strength
enabling dividends
RMB 699 million
PAHI cash dividend:
(ZAR 1.8 billion)4
Private health sector well
positioned for growth
Solvency (RMB billion) and
Comprehensive SCR (%)
Commercial health insurance share of
innovative drug coverage (%) 1
44% 44%
7%
44%
49%
12%
2025 2035
Out of Pocket
Commercial Health Insurance
Basic Medical Insurance
Supportive government
systematic medical and
health reforms
334%
320%
267%
231%
277%
2. PAHI's market share of accessible sectors of the market	1. ChinaRe Report (2025) 3. Note: In transition phase to IFRS-17, there are discrepancies between the accounting standards 4. 100% PAHI gross of withholdings tax. Assumes spot rate as at dividend declaration

-- 58 of 62 --

59
Vitality
Proprietary
data
Dynamic
risk
assessment
Vitality.AI
recommender
Incentivised
engagement
Insurance
integration
Partner Markets	
North America	
Europe	
Asia	
UK

-- 59 of 62 --

60
Summary
Excellent start to the
five-year growth
corridor
1
2
3
Robust FY25
performance
Clarity of strategy and
growth through two
business composites
Increasing relevance of the
Group’s Vitality Shared-value
model
4 12.5% to 17.5%
average earnings growth
p.a.
(FY25-FY29)
20% to 30%
average earnings growth
p.a.
(FY25-FY29)
Normalised
profit
growth
15-20%
CAGR
FY25-FY29
Normalised profit
+29%
to R15 210m
New business1
-2%
to R26 486m
Headline
earnings
+30%
to R9 625m
Normalised headline
earnings
+30%
to R9 781m
Non-insurance
income
+12%
to R6 643m
excl. Sasolmed
+8%

-- 60 of 62 --

61
Presentation disclaimer
This presentation may contain forward looking statements with respect to certain of
Discovery’s plans and its current goals and expectations relating to its future performance
and results. All forward looking statements involve risk and uncertainty because they relate
to future events and circumstances which are beyond Discovery’s control. Accordingly,
Discovery’s actual future financial performance and results may differ. Any reference to
future financial performance has not been reviewed or reported on by the Group’s auditors.

-- 61 of 62 --

Audited
Results
and cash dividend declaration
for the year ended 30 June 2025

-- 62 of 62 --